Information  X 
Enter a valid email address

Faron Pharma. Oy (FARN)

  Print      Mail a friend

Wednesday 16 May, 2018

Faron Pharma. Oy

PDMR Shareholding

RNS Number : 3448O
Faron Pharmaceuticals Oy
16 May 2018
 

 

Faron Pharmaceuticals Oy

("Faron" or the "Company")

 

  PDMR Dealing

 

 

TURKU - FINLAND, 16 May 2018 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 16 May 2018 it was notified that on 15 May 2018 Dr Jonathan Knowles, a Non-Executive Director of Faron has acquired 7,200 ordinary shares in Faron at an average price of 118.00 pence per ordinary share and 1,300 ordinary shares in Faron at an average price of 116.97 pence per ordinary share.

 

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

                                                                                                                                  

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jonathan Knowles                  

 

2

Reason for notification

 

 

 

a.

Position/Status

Person discharging managerial responsibilities

 

Non-Executive Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Faron Pharmaceuticals Oy

b.

LEI

7437009H31TO1DC0EB42

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares

ISIN: FI4000153309


b.

Nature of the transaction

Purchase of ordinary shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


118.00 GBPp

116.97 GBPp

7,200

1,300


 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

8,500

 

GBP 10,016.61

 

e.

Date of the transaction

May 15, 2018

f.

Place of the transaction

Turku

 

 

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
[email protected]

Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: [email protected]

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: [email protected]

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome ("ARDS"). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHSFEFMMFASEII

a d v e r t i s e m e n t